FAQ 04 // plain answers
Thymosin alpha-1 FAQ: clear answers from the studies
Twenty-four common questions, with the answer and its limit.
Thymosin alpha-1 is a small natural protein
Researchers first found this small natural protein in a calf’s thymus. In 1977, they mapped its twenty-eight linked parts [1]. Thymalfasin is the man-made copy sold as Zadaxin. The brand appears outside the US in 30+ countries for hepatitis B and C [20].
Thymosin alpha-1 changed immune guide cells in labs
The drug works with two cell message spots, numbered 9 and 2 [4][5]. Another cell message has the number 2. Those numbers are only lab labels. Lab tests found more help for some defenses, but they can’t show that you’ll benefit.
Thymosin alpha-1 has several studied uses
Researchers studied it in hepatitis B and C. A form is approved for those liver illnesses in 30+ countries [12]. Other studies covered severe sepsis [6], lung cancer [15] and severe COVID-19 [8].
Reviews from 2023 joined some COVID studies. One older study tested it with a flu shot in people with weak immune systems [18]. You can’t assume every use fits your illness.
Thymosin alpha-1 lacks FDA approval
Thymosin alpha-1 isn’t FDA-approved in the United States. Thymalfasin, the man-made form, is approved in 30+ countries for hepatitis B and C. In December 2024, an FDA group reviewed whether mixing pharmacies could use forms of this drug [21].
Those pharmacies make medicine for one person at a time. The review wasn’t drug approval. It also didn’t prove the drug safe for you.
Some people were left out of Thymosin alpha-1 studies
Studies left out pregnant or nursing people [20]. They also barred transplant patients taking drugs that quiet the immune system. People with active autoimmune disease were barred too. In that illness, your defenses can harm your body. The concern came from how the drug works, not proved harm.
Thymosin alpha-1 most often caused brief shot-site pain
Most people in the studies handled the drug well [20]. Brief pain and mild redness at the shot spot were most common. Some users report more energy or a better feeling. Those are personal reports, not findings from a study that compared care groups. The studies didn’t measure those feelings.
Thymosin alpha-1 hasn’t been shown to boost energy
No study used energy as its main test. Some hepatitis and cancer studies recorded less tiredness. Tiredness wasn’t the main thing they set out to test. Better control of illness could explain the change, so a quick lift wouldn’t prove the drug worked.
Thymosin hasn’t been proved to slow aging
Your thymus gland shrinks with age, and some immune defenses weaken. Gravenstein studied older men getting a flu shot [18]. Perruccio studied people healing after a transplant [19].
Both groups had weak immune defenses. Thymosin alpha-1 studies didn’t test healthy adults for slower aging. You can’t use their results as proof about your own aging.
Thymosin alpha-1 study results took time
Hepatitis B and C studies checked virus control at 6 months [12][14]. Sepsis studies counted deaths by 28-day [6]. No sound study gives you a quick start time. A fast feeling wouldn’t prove an immune benefit, and the studies checked illness, not a feeling.
Thymosin alpha-1 study lengths differed
Hepatitis studies ran for 6 months [12][14]. One sepsis plan ran for 7 days [6]. A flu-shot plan ran for 4 weeks [18]. Doctors don’t have one study-backed course for home use. Those periods don’t tell you how long you need care.
Thymosin alpha-1 doses depended on the illness
Hepatitis studies often used 1.6 mg in two skin shots each week for 6 months [20]. One sepsis study used 1.6 mg in a skin shot twice daily. That lasted for 5 days, followed by once daily for 2 days [6]. These aren’t dose plans for you.
A Thymosin alpha-1 dose needs medical judgment
Studies used amounts from 900 micrograms to 16 mg in skin shots. A microgram is one-thousandth of a milligram. The most common amount was 1.6 mg twice weekly [20]. Early cancer studies used higher amounts. This range isn’t a dose built around your health or medicines.
No study found a best time for Thymosin alpha-1
Most studies didn’t tie the shot to morning or night [20]. Researchers chose twice-weekly plans because the immune effect can outlast your blood level. Published work doesn’t show that the drug acts better at one time. The studies don’t give you a best clock time, and your daily routine wasn’t tested.
Thymosin alpha-1 and TB-500 (Thymosin beta-4) aren’t the same
TB-500 is a man-made part of Thymosin beta-4. Researchers study that protein for tissue repair. Thymosin alpha-1 is a different protein with twenty-eight linked parts.
Researchers study the drug for effects on your immune system. The shared word thymosin can mislead you. The two proteins don’t work alike. Their uses and results aren’t the same.
Thymosin alpha-1 side effects were usually mild
Pain and brief redness at the shot spot were most common. Up to 16 mg, no problem made researchers set a lower dose limit [20]. That doesn’t prove the amount is safe for everyone. Some people with higher risks weren’t in the studies.
Thymosin alpha-1 leaves blood faster than its effect ends
Half-life means the time for half the drug to leave your blood. It’s about 2 hours after a skin shot. The effect on immune cells may last 48–72 hours [20]. That longer effect helps explain why some studies used shots twice a week.
Thymosin alpha-1 studies mostly used shots
Studies behind approvals used skin shots [20]. Early work tried the drug by mouth, nose or vein. Those weren’t the main ways.
Pills sent little drug into the blood. The stomach broke the protein down first. The main results don’t cover pills.
Zadaxin is a brand of thymalfasin
Zadaxin is SciClone Pharmaceuticals’ brand of thymalfasin. Thymalfasin is man-made Thymosin alpha-1. You can find the brand in 30+ countries, with most approvals for hepatitis B and C [20]. Most studies of how the drug works used this form, and approval abroad doesn’t give you FDA approval in the United States.
Thymosin alpha-1 isn’t proved for long COVID
Studies from 2020–2023 offer early signs, not firm proof. Liu’s 2020 Wuhan work and Sun’s 2021 study found fewer deaths in severe COVID-19 [8][9]. Matteucci’s 2023 work found more normal immune-cell counts in long-COVID patients [11].
Researchers looked back after care had been chosen. They didn’t use chance to form the groups. Other care may have caused part of the change. Your long-COVID course may differ.
Thymosin alpha-1 isn’t a steroid
No. It is a hormone, a body message, built as a protein with twenty-eight linked parts. It isn’t like cortisone or muscle-building steroids.
The drug acts on two cell message spots, numbered 9 and 2 [4][5]. Those spots receive messages. Steroids act in a different way.
Thymosin alpha-1 was added to cancer care in studies
Researchers added the drug to usual care for several cancers. Those included lung cancer, melanoma skin cancer and liver cancer. They hoped to restore immune cells weakened by cancer or its treatment [15][16][17]. The studies don’t show that the drug kills cancer by itself. It isn’t a cancer cure.
Active autoimmune disease kept people out of Thymosin Alpha-1 studies
Studies often left out people with active autoimmune disease [20]. In that illness, your defenses can harm your own tissue. Thymosin alpha-1 can raise some immune-cell activity.
Researchers feared that extra activity could worsen tissue harm. The ban was a safety step. It didn’t come from bad events that kept appearing in the studies.
Thymosin Alpha-1 wasn’t named on the WADA list
The World Anti-Doping Agency list didn’t name Thymosin alpha-1 as of 2025. Still, sports rules can cover hormone drugs in broad groups. The name alone may not settle the rule. If you compete, your sport’s own anti-doping office gives the binding answer. This page isn’t enough.
Thymosin alpha-1 reviews bring the studies together
Dominari’s 2020 review is the best-known broad review of Thymosin alpha-1 [2]. It covers hepatitis, sepsis, cancer, COVID-19 and care for weak immune systems. This site reads that same study set one illness at a time. We checked each number against the named paper, and you can use the source list to read the paper yourself.